-
Subject Areas on Research
-
(2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy.
-
211At radiocolloid therapy: further observations and comparison with radiocolloids of 32P, 165Dy, and 90Y.
-
A novel silicon array designed for intraoperative charged particle imaging.
-
Applications of 211At and 223Ra in targeted alpha-particle radiotherapy.
-
Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy.
-
Astatine-211: production and availability.
-
Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.
-
Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma.
-
Cytotoxicity of alpha-particle-emitting 5-[211At]astato-2'-deoxyuridine in human cancer cells.
-
Cytotoxicity of alpha-particle-emitting astatine-211-labelled antibody in tumour spheroids: no effect of hyperthermia.
-
Engineered modular recombinant transporters: application of new platform for targeted radiotherapeutic agents to alpha-particle emitting 211 At.
-
Exposure of human osteosarcoma and bone marrow cells to tumour-targeted alpha-particles and gamma-irradiation: analysis of cell survival and microdosimetry.
-
High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use.
-
Labeling Monoclonal Antibody with α-emitting 211At at High Activity Levels via a Tin Precursor.
-
Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images.
-
Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma.
-
Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate.
-
Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates.
-
Radioimmunotherapy with alpha-particle emitting radionuclides.
-
Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 2: radiolytic effects of 211At alpha-particles influence N-succinimidyl 3-211AT-astatobenzoate synthesis.
-
Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 3: alpha-particle-induced radiolytic effects on the chemical behavior of (211)At.
-
Radiopharmaceutical chemistry of targeted radiotherapeutics, part 1: effects of solvent on the degradation of radiohalogenation precursors by 211At alpha-particles.
-
Radiopharmaceutical chemistry of targeted radiotherapeutics, part 4: Strategies for 211At labeling at high activities and radiation doses of 211At α-particles.
-
Radon dosimetry based on the depth distribution of nuclei in human and rat lungs.
-
Synthesis and preliminary evaluation of 211At-labeled inhibitors of prostate-specific membrane antigen for targeted alpha particle therapy of prostate cancer.
-
Targeted Radiotherapy with Alpha-Particle Emitting Radionuclides Seminar, November 18, 2004, Cracow, Poland.
-
Targeted alpha-particle therapy of microscopic disease: Providing a further rationale for clinical investigation.
-
Targeted therapy using alpha emitters.
-
Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab.
-
Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia.
-
Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis.
-
Keywords of People